Utah Medical Products, Inc. — Earnings Quality Grade C
UTMD · Healthcare
Some red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 38 days, change +0 days YoY
AR outpaced revenue for 2 consecutive years
Revenue -5.8%, CFFO -0.9%. Cash follows revenue
Expense Quality
Inventory -10.0% vs COGS -1.4%. Normal
CapEx growth 57.9% is >2x revenue growth -5.8%
SG&A/Gross Profit = 45.1%. Normal
Gross margin 57.1%, change -1.9pp. Stable
Cash Flow Quality
CFFO/NI = 1.30. Profits backed by cash
FCF $0.0B, FCF/NI = 1.27
Accruals ratio = -2.8%. Low accruals
Cash $0.1B covers debt $0.0B
Balance Sheet Health
Goodwill+Intangibles $0.0B = 12% of equity. Manageable
Debt/EBITDA = 0.0x. Healthy
Insufficient data
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -9% YoY. Normal
Manipulation Score
M-Score = -2.59 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor UTMD continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25